Author: BusinessWire

Moderna ranked number 1 overall; also ranked number 1 in the biotechnology category
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it …

BURLINGTON, N.C.–(BUSINESS WIRE)–Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has been named to Fast Company magazine’s list of 2021 Most Innovative Companies. Since 2008, the annual list has been the definitive…

BURLINGTON, N.C.–(BUSINESS WIRE)–Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has been named to Fast Company magazine’s list of 2021 Most Innovative Companies. Since 2008, the annual list has been the definitive…

Johnson & Johnson Innovation – JJDC, Inc., RTW Investments, LP and Wille AG participated in the financing round

Funding will help advance lead product candidate BRIMOCHOL into pivotal registration studies

SEATTLE–(BUSINESS WIRE)–Visus Thera…

Johnson & Johnson Innovation – JJDC, Inc., RTW Investments, LP and Wille AG participated in the financing round

Funding will help advance lead product candidate BRIMOCHOL into pivotal registration studies

SEATTLE–(BUSINESS WIRE)–Visus Thera…

Johnson & Johnson Innovation – JJDC, Inc., RTW Investments, LP and Wille AG participated in the financing round

Funding will help advance lead product candidate BRIMOCHOL into pivotal registration studies

SEATTLE–(BUSINESS WIRE)–Visus Thera…

– First patient dosed in the multiple ascending dose portion of Phase 1/2a MONARCH study of STK-001 in Dravet syndrome –

– Preliminary safety and PK data from the single ascending dose portion of MONARCH still expected in H2 2021 –

– As of December …

Johnson & Johnson Innovation – JJDC, Inc., RTW Investments, LP and Wille AG participated in the financing round

Funding will help advance lead product candidate BRIMOCHOL into pivotal registration studies

SEATTLE–(BUSINESS WIRE)–Visus Thera…

SAN FRANCISCO–(BUSINESS WIRE)–Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-in-human genomic platform with machine learning, announced today that Steve Kanes, M.D., Ph.D., Chief Me…

– First patient dosed in the multiple ascending dose portion of Phase 1/2a MONARCH study of STK-001 in Dravet syndrome –

– Preliminary safety and PK data from the single ascending dose portion of MONARCH still expected in H2 2021 –

– As of December …